<div id="readability-page-1"><p>Research analysts at StockNews.com initiated coverage on shares of <span>Cytosorbents (NASDAQ:CTSO - Get Free Report)</span> in a report released on Sunday. The brokerage set a &#34;hold&#34; rating on the medical research company's stock.</p><p>Several other equities analysts have also recently issued reports on CTSO. D. Boral Capital  reiterated a &#34;buy&#34; rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday. HC Wainwright  reiterated a &#34;neutral&#34; rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned  a buy rating and one  has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $4.67.</p><p><b>Get Our Latest Analysis on CTSO</b></p><h2>Cytosorbents Stock Up 1.8 %</h2><p>Cytosorbents stock opened at $0.94 on Friday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The firm has a market cap of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The business's 50-day moving average price is $0.92 and its 200 day moving average price is $1.02. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Atomi Financial Group Inc. acquired a new position in  Cytosorbents during the third quarter worth $51,000.  Geode Capital Management LLC increased its stake in shares of  Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter.  Finally, Sargent Investment Group LLC raised its position in shares of  Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Hedge funds and other institutional investors own  32.87% of the company's stock. </p><h2>Cytosorbents Company Profile</h2> (Get Free Report)<p>Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Cytosorbents</li><li>Why Invest in High-Yield Dividend Stocks?</li><li>Quantum Opportunity: Skywater Technology's Long-Term Potential</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>Nebius Group: The Rising Star in AI Infrastructure</li><li>3 Ways To Invest In Coffee, Other Than Drinking It</li><li>MarketBeat Week in Review – 12/30 - 1/03</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Trump’s Sending THIS Crypto Higher on Purpose <span><span>(From Crypto 101 Media)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng"/></p><h2>Should you invest $1,000 in Cytosorbents right now?</h2><p>Before you consider Cytosorbents, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.</p><p>While Cytosorbents currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CTSO

<p>Cytosorbents (NASDAQ:CTSO) has received a "hold" rating from StockNews.com, which initiated coverage on the stock. Other analysts have varied opinions, with D. Boral Capital giving a "buy" rating and a $10 target price, while HC Wainwright set a neutral rating with a $1 price objective. The stock opened at $0.94, with a 52-week range of $0.70 to $1.59. Institutional investors hold 32.87% of the company, which specializes in medical devices for blood purification.</p>

Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com